arrow
G

Guille, Arnaud

institut paoli-calmettes
H指数:0
被引数:10

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Whole-exome profiles of inflammatory breast cancer and pathological response to neoadjuvant chemotherapy

炎性乳腺癌的全外显子组特征和新辅助化疗的病理反应

2024-10-270
OAAI
Absence of chromosome axis protein recruitment prevents meiotic recombination chromosome-wide in the budding yeast Lachancea kluyveri

缺乏染色体轴蛋白募集会阻止出芽酵母Lachancea kluyveri的全染色体减数分裂重组

2024-03-133
OAAI
Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network
2023-06-236
OAAI
Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate

克服对Anti-Nectin-4抗体-药物偶联物的抗性

2022-05-0928
OA
Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy
2022-04-192
OA
Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study
2022-03-304
OA
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia

RAS激活通过线粒体氧化代谢诱导急性髓系白血病MEK抑制的合成致死率

LEUKEMIA
IF13.4
2022-03-3020
OAAI
BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells
2022-02-0216
OAAI
TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients

TAKTIC: LY2780301 (一种p70S6K/AKT抑制剂) 联合每周紫杉醇治疗HER2-negative晚期乳腺癌患者的前瞻性、多中心、非对照、IB/II期研究

2021-12-0111
OAAI